Looks like it was published yesterday TF:
https://jitc.bmj.com/content/11/10/e006966.info
...taken advantage of the (second) overreaction to the second auditor delay with a 150k buy.
"....BDO has form on this...and more than once..."
Time for a new auditor I seems.
Not too unhappy though as I, and by the looks of it others, have used it as a cheeky top up opportunity.
To be fair you can't argue with the clarity of the RNS, stating exactly what is going on, Scancell in the past would have no doubt been vague about which would have caused uncertainty. Scancell have seen to have improved noticeably in this department.
TF Dr Semhi is a she.
I guess we agree to disagree Bojo.
Your argument falls over for me somewhat because of all the numerous pre-clinal/early phase deals that happen all the time. IMO.
Moonparty - you've absolutely nailed that reply. Very well said.
Also for those who seem to think deal/collaboration news is eons away, why are you invested here in the short/medium term? Surely your money is better invested elsewhere in the meantime if that's what you think?
Thanks ciaskin, and yes, indeed it does look almost like it was planned!
But I'm sure it's just a coincidence π
Can someone please remind me of the near term upcoming events/conferences itinerary for Scancell.
I think I'm getting them mixed up.
Also, have Scancell attended the World Vaccine Congress before?
Hi CW, who is Eep?
Correct link:
https://www.marketwatch.com/story/tempest-therapeutics-stock-jumps-1-900-as-liver-cancer-treatment-shows-promise-5ba57298
But an increase of two and bit months?
But even the UK market should have recognised the impact of those SCIB1 results more than it did, no?
It's bizarre IMO.
I also followed the tempest therapeutics news with some interest also, an insane move in the SP.
But looking at their actual data release:
"Patients treated with the triple therapy had median progression-free survival of seven months, versus 4.3 months for those treated only with Tecentriq and Avastin, Tempest said."
https://www.marketwatch.com/story/tempest-therapeutics-shares-head-back-to-earth-after-4-000-gain-be2f6b73
Whilst probably difficult to compare like for like (different targets etc) the recent SCIB1 results are far far more impressive are they not? Relatively speaking.
As others have mentioned if Scancell were in the USA and they released that SCIB1 RNS there, can you imagine the move?*
*I don't fully understand the "poison pill" stock change however and how much it was a factor in the move.
Darkprince you said the same thing when the audit results date change rns was announced, then you went all quiet as the price recovered π.
You're game is obvious.
Haven't you got a bridge you should be sitting under?
.
Interesting that the CFO is also presenting?
Cannot buy anywhere between 1000-30000 shares atm, not tried higher amounts.
Ruckrover - likewise, don't let your obsession with inanaco cloud your view.
Likewise Dibs61, grateful for the opportunity a short while ago.
It's 14.475p to buy a 1000 for me on my broker atm.
Purely IMO those dates are too much of a coincidence. If it's related to a shortage of auditors, the specific two week seems odd as does the very last min reschedule.